ALK and neuroblastoma: These findings indicate that the combination of mutated ALK and MYCN signaling is sufficient to induce NB from sympathoadrenal progenitors and that ALK (p.F1174L) mutation potentiates the oncogenic activity of MYCN in NB [244].